Every 424B that CollPlant Biotechnologies Ltd (CLGN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CLGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLGN filings page.
CollPlant Biotechnologies Ltd. is registering for resale by existing investors up to 31,047,068 ordinary shares. These comprise 4,464,707 PIPE Shares and 26,582,361 shares issuable upon exercise of pre-funded, Series A, Series B and placement agent warrants issued in a June–July 2026 private placement.
The company will not receive proceeds from Selling Shareholders’ resales but may receive up to $8.0 million in gross proceeds if all warrants are exercised for cash, to be used for general corporate purposes, working capital, R&D and evaluating strategic combinations. As of March 31, 2026, 14,443,500 shares were outstanding, increasing to 18,908,207 on an as-adjusted basis after the PIPE, which generated approximately $2.3 million in net proceeds.
CollPlant develops rhCollagen-based products for regenerative and aesthetic medicine, including dermal fillers and 3D-bioprinted breast implants. The company reports ongoing losses, negative operating cash flows, and states its current cash resources are not sufficient for the next 12 months, raising substantial doubt about its ability to continue as a going concern absent additional financing.
CollPlant Biotechnologies Ltd. is registering for resale up to 3,296,000 ordinary shares issuable upon exercise of private placement warrants (1,600,000 series A; 1,600,000 series B; 96,000 placement agent warrants). This registration is a resale registration by the selling shareholders; the company will not receive proceeds from resale.
The prospectus names the selling shareholders and notes ordinary shares outstanding of 14,415,128 as of March 17, 2026. The company may receive proceeds only if the warrants are exercised for cash (full cash exercise would yield approximately $4.15 million). Trading symbol: CLGN; last reported sale price: $0.37 per share (April 20, 2026).
CollPlant Biotechnologies Ltd. is raising equity capital through a primary offering of 1,600,000 ordinary shares at $1.25 per share, for gross proceeds of $2.0 million and estimated net proceeds of about $1.7 million. After placement fees and expenses, the company expects to receive approximately $1.86 million before expenses and plans to use the funds for general corporate purposes, including working capital and research and development.
Following the offering, ordinary shares outstanding are expected to increase from 12,803,006 to 14,403,006, implying immediate dilution for new investors, with as-adjusted net tangible book value rising to $0.76 per share versus a $1.25 purchase price. In a concurrent private placement, investors will receive unregistered Series A and Series B warrants to purchase up to 3,200,000 additional ordinary shares at $1.25 per share, which could lead to further dilution if exercised.
The company notes that current cash resources, including expected net proceeds from this offering, are not sufficient to fund operations for the next 12 months, and its ability to continue as a going concern depends on securing additional financing or milestone payments under its AbbVie development agreement. CollPlant recently achieved a $2 million development milestone with AbbVie and remains focused on rhCollagen-based regenerative and aesthetic products, while operating under reduced reporting requirements as a foreign private issuer listed on Nasdaq under the symbol “CLGN”.